Using a pre-defined cutoff of ≥5% of tumor cells by immunohistochemistry, or a harmonized equivalent cutoff by an orthogonal method (reverse phase protein array/RPPA), tsMHC-II was confirmed to be predictive of pCR and event-free survival (EFS) to PD-1/PD-L1 inhibitors in addition to NAC but not to NAC alone14. The gene discussed is CD274; the disease is neoplasm.